Elomo 25 mg contains eltrombopag, a medication that helps stimulate the production of platelets in the blood. It is especially useful in conditions where the body is not making enough platelets or where they are being destroyed faster than they can be replaced. Eltrombopag is classified as a thrombopoietin receptor agonist and is taken orally.

This medicine provides a non-invasive option for patients with certain types of low platelet disorders and has become a significant advancement for those who either do not respond well to standard treatments or require long-term management.

Mechanism of Action

Eltrombopag works by activating the thrombopoietin receptor found on bone marrow cells. Thrombopoietin is a natural protein that signals the bone marrow to make more platelets. By mimicking this protein, eltrombopag boosts platelet production in the bone marrow.

Unlike blood transfusions or immune-suppressing medications, eltrombopag acts directly on the cells responsible for producing platelets, offering a more targeted approach to managing chronic low platelet counts.

Uses

Elomo is prescribed for the treatment of several platelet-related conditions, including:

• Chronic immune thrombocytopenia (ITP) in adults and children who have not responded well to other treatments such as corticosteroids or immunoglobulins

• Thrombocytopenia in patients with chronic hepatitis C, where low platelets prevent or complicate antiviral treatment

• Severe aplastic anemia, particularly in those who have not responded adequately to immunosuppressive therapy

  Adverse Effects

  Like all medications, eltrombopag can cause side effects, although not everyone experiences them. Most side effects are manageable, but some may require close monitoring.

  Common Side Effects

  • Headache, often mild and temporary

  • Nausea or indigestion

  • Tiredness or fatigue

  • Muscle aches

  • Mild liver function changes, seen in blood tests

  • Loss of appetite